High-Dose Omega-3 Fatty Acid Shows Survival Benefit in Colorectal Cancer Liver Metastases Trial

Colorectal cancer can spread to the liver, where secondary tumours may sometimes be removed surgically. Even after surgery, cancer can recur, so researchers are investigating supportive strategies that might improve outcomes alongside established cancer treatment. EPA is an omega-3 fatty acid found in some fish and available in supplement formulations. In the EMT2 Phase 3 trial, researchers studied high-dose EPA given around the time of surgery to patients with colorectal cancer liver metastases. The reported results indicated longer overall survival in the EPA group than in the placebo group. This is clinically relevant because survival outcomes are more meaningful than laboratory markers alone. Nevertheless, interpretation requires the full trial results, including the size of the benefit, confidence intervals, adverse effects, treatment schedules and characteristics of the patients who participated. The findings do not mean that ordinary fish-oil supplements can treat cancer or that patients should take high doses of EPA without medical advice. Cancer patients may have specific bleeding risks, medication interactions or nutritional needs, particularly around surgery.